AstraZeneca & Ionis Pharmaceuticals
2 shared events · Importance 3 · Last updated Jul 23, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
AstraZeneca: AstraZeneca's stock fell 5.7% after the trial failure; it faces investor investigations and potential legal liability.
Ionis Pharmaceuticals: Ionis's stock plunged 23.9%, losing over $3.3 billion in market cap; it is the primary target of multiple securities investigations.
Jul 09, 2026 · 46 articles
Business
AstraZeneca: AstraZeneca is the central company, facing another pipeline setback with the discontinuation of the volrustomig trial. Despite this, it reported positive results from other trials and reaffirmed its 2030 revenue target, with shares rising slightly.
Ionis Pharmaceuticals: Ionis Pharmaceuticals is the partner for Wainua, which failed in a heart disease trial earlier this year, contributing to the series of setbacks for AstraZeneca.
Aug 17, 2026 · 20 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how AstraZeneca and Ionis Pharmaceuticals interact across events, view sentiment trends, and discover connected entities.
Open Dashboard